BioNTech SE
88.115USD
-1.5550 (-1.73%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BNTX.
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 17.3B | 3.8B | 2.8B | 2.9B | 1.8B | 1.8B |
| Q1 | — | — | — | — | 118.1M | — |
| Q2 | — | — | — | 260.8M | 105.6M | — |
| Q3 | — | — | — | 1.5B | 1.0B | — |
| Q4 | — | — | — | 907.4M | 516.4M | — |
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 37.77 | 3.83 | -2.77 | -4.70 | -4.68 | -4.81 |
| Q1 | — | — | — | — | -2.10 | — |
| Q2 | — | — | — | -1.60 | -3.24 | — |
| Q3 | — | — | — | -.120 | .758 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| -1.25 |
| -.838 |
| — |
Debt level and coverage